The potential use of tetracalcium phosphate in vertebral augmentation: A study in a sheep model

四钙磷酸盐在椎体增强术中的潜在应用:一项绵羊模型研究

阅读:1

Abstract

BACKGROUND: Percutaneous vertebroplasty (PVP) and percutaneous kyphoplasty (PKP) are widely used to treat vertebral frac-tures. However, the standard filler material, polymethylmethacrylate (PMMA), presents significant drawbacks, including thermal dam-age, allergic reactions, and poor biocompatibility. Tetracalcium phosphate (TTCP), a calcium phosphate cement (CPC), has emerged as a promising alternative due to its superior biocompatibility, osteoconductivity, and ability to integrate with natural bone. This study aimed to evaluate the feasibility of TTCP for vertebral augmentation in a preclinical sheep model, focusing on biomechanical stability, biocompatibility, and osteogenic potential. METHODS: Five Akkaraman sheep underwent PKP with TTCP at three lumbar vertebral levels (L2-L4). Under general anesthesia, TTCP cement was injected into cavities prepared according to the standard PKP procedure. Postoperative care included analgesia and antibiotics. Four animals were followed for 12-14 weeks, and one for 25 weeks. At the end of the study period, the animals were euthanized and vertebrae were harvested for biomechanical testing using a Shimadzu AG-IS 100 kN machine. Histological evaluation was performed to assess ossification stages according to Shapiro's classification. Statistical analysis was conducted using paired t-tests (p<0.05). RESULTS: One animal was euthanized prematurely due to infection, while four completed the study without complications. Biomechanical analysis demonstrated no significant difference in compressive strength between treated and untreated vertebrae (p>0.05). Histological examination revealed osteoblastic activity, progressive mineralization, and successful bone integration. CONCLUSION: TTCP demonstrated promising biomechanical and biophysiological properties for vertebral augmentation. However, its use in infected sites and in the presence of metabolic bone disorders may be limited. Further clinical studies are required to validate its long-term efficacy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。